Changes in Hong Kong stocks | Baiosaitu-B (02315) rose nearly 6% in the first half of the year, net profit returned to the mother and the highest advance increase of more than 4 times, and the two major business lines achieved two-wheel drive

The Zhitong Finance App learned that Biosetu-B (02315) rose nearly 6%. As of press release, it had risen 5.85% to HK$58.8, with a turnover of HK$53.277 million.

According to the news, Baiosaitu announced that it is expected to achieve operating income of 936 million yuan to 946 million yuan in the 2026 semi-year, an increase of 50.80%-52.41%; net profit attributable to owners of the parent company is 236 million yuan to 246 million yuan, an increase of 392%-413% year on year. The change in performance is mainly due to the company's forward-looking R&D and high-quality customer network. The two major business lines achieved two-wheel drive and rapid revenue growth. At the same time, scale effects were shown, lean management was deepened, gross margin increased, and profit margin was reduced, and profitability increased significantly.

As of December 31, 2025, Baiosetu has signed more than 350 drug cooperative development/licensing/transfer agreements. The company's sub-brand Baiao Animal has established thousands of gene-edited animal/cell models, has the world's leading target humanized mouse library, and provides global customers with full-chain capability support such as preclinical pharmacological efficacy research, gene editing services and model construction.